AAMI TIR42-2021 PDF

Full title and description

AAMI TIR42:2021 — Evaluation of particulate associated with vascular medical devices. This Technical Information Report provides guidance for defining appropriate test methods, identifying sources of particulate, assessing clinical risk from particulate exposure, and establishing product particulate limits for intravascular/vascular medical devices that contact circulating blood.

Abstract

This TIR offers practical recommendations and explanatory material to help manufacturers and testing laboratories evaluate the tendency of vascular devices to release particulate matter, select and apply analytical methods (particle counting, microscopy, chemical identification), determine particulate sources (materials, environment, clinical use), and develop risk‑based particulate limits and reporting practices. It emphasizes a clinical risk assessment approach for translating analytical findings into device-specific acceptance criteria.

General information

• Status: Current (document in force as published).
• Publication date: 31 March 2021.
• Publisher: Association for the Advancement of Medical Instrumentation (AAMI).
• ICS / categories: 11.100 — Laboratory medicine (particulate analysis / medical device testing).
• Edition / version: AAMI TIR42:2021 (Technical Information Report, 2021 edition).
• Number of pages: 47 pages.

Scope

Addresses particulate released from intravascular and vascular medical devices that come into direct contact with circulating blood. The report guides test method selection, particulate source identification, analytical characterization, clinical risk assessment of particulate exposure, and the derivation of product particulate limits and reporting practices. It is intended as guidance to supplement device‑specific testing and regulatory requirements.

Key topics and requirements

• Definitions and classification of particulate relevant to vascular devices (size, composition, visible vs. subvisible).
• Identification of particulate sources: materials, manufacturing residues, packaging, environment, and clinical use.
• Recommended analytical techniques: light‑obscuration/particle counters, microscopic filter analysis, spectroscopy and microscopy for material identification.
• Test design and sample preparation guidance, including extraction and reporting conventions for particles by size ranges (e.g., >10 µm, >25 µm where relevant).
• Risk‑based framework for establishing particulate limits and clinical relevance assessment (links to risk management practices).
• Recommendations for documentation, trending, root‑cause analysis, and corrective actions when particulate issues are detected.

Typical use and users

Primary users are medical device manufacturers (R&D, materials, and quality engineers), analytical testing laboratories, regulatory and clinical affairs staff, notified bodies and regulatory reviewers, and clinicians involved in device safety assessment. The TIR is used to design particulate testing programs, interpret particle data in clinical context, and support regulatory submissions and post‑market investigations.

Related standards

Commonly used alongside and referencing other standards and guidance documents, for example the earlier AAMI TIR42:2010 (superseded by the 2021 edition), ISO risk‑management guidance such as ISO 14971 (risk management for medical devices), and pharmacopeial/analytical methods frequently consulted for particulate testing (e.g., USP general chapters on particulate matter in injections). Device cleanliness and particle analysis standards such as ISO 19227 / ISO 16232 and relevant ASTM methods are also often considered.

Keywords

particulate, particles, vascular medical devices, intravascular, particle counting, microscopy, clinical risk assessment, particulate limits, AAMI TIR42, device cleanliness

FAQ

Q: What is this standard?

A: AAMI TIR42:2021 is a Technical Information Report titled "Evaluation of particulate associated with vascular medical devices" that gives guidance on testing for and assessing particulate release from devices that contact circulating blood.

Q: What does it cover?

A: It covers sources of particulate, recommended analytical methods (e.g., particle counting and microscopic/chemical characterization), test sample preparation, and a risk‑based approach to determine clinical relevance and set product particulate limits.

Q: Who typically uses it?

A: Device manufacturers (R&D, quality, regulatory), contract testing laboratories, regulatory reviewers, and clinicians concerned with device‑related particulate hazards. It is used to develop test programs, interpret results, and inform risk management.

Q: Is it current or superseded?

A: The 2021 edition is the current AAMI TIR42 document, published 31 March 2021; it revises and replaces the prior AAMI TIR42:2010. Users should check for any amendments or newer revisions before relying on it for compliance decisions.

Q: Is it part of a series?

A: TIR42 is a stand‑alone Technical Information Report within AAMI’s body of guidance documents. It complements other AAMI, ISO, ASTM, and pharmacopeial documents related to device cleanliness, biological evaluation, and risk management rather than being a numbered series.

Q: What are the key keywords?

A: particulate, particle analysis, vascular devices, intravascular, particulate limits, particle counting, microscopy, clinical risk assessment, device cleanliness.